These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 94552)

  • 1. Correlation of a specific chromosomal marker, 21q-, and retroviral indicators in patients with thrombocythemia.
    Fuscaldo KE; Erlick BJ; Fuscaldo AA; Brodsky I
    Cancer Lett; 1979 Jan; 6(1):51-6. PubMed ID: 94552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute lymphocytic and myelomonocytic leukemia associated with low platelet counts and a 21q- marker chromosome.
    Alimena G; Dallapiccola B; De Cuia MR; Mandelli F; Mitelman F
    Hum Genet; 1981; 57(3):329-31. PubMed ID: 6941924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
    Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
    Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of platelets and virus-like particles by busulfan in myeloproliferative disorders.
    Fuscaldo AA; Erlick BJ; Brodsky I; Fuscaldo KE
    Leuk Res; 1980; 4(1):105-17. PubMed ID: 6157962
    [No Abstract]   [Full Text] [Related]  

  • 6. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MYELOPROLIFERATIVE DISORDERS].
    MARCIACQ ALTAFULLA
    Arch Med Panamenos; 1963 Aug; 12():149-59. PubMed ID: 14164997
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombocytosis and thrombocythaemia.
    Murphy S
    Clin Haematol; 1983 Feb; 12(1):89-106. PubMed ID: 6340888
    [No Abstract]   [Full Text] [Related]  

  • 9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [THROMBOCYTHEMIAS AND THROMBOCYTOSIS].
    PEDRO PONS A; FARRERASVALENTI P; ROZMAN C; RIBASMUNDO M; SANS SABRAFEN J; CASTILLO R
    Med Clin (Barc); 1964 Oct; 43():215-28. PubMed ID: 14306855
    [No Abstract]   [Full Text] [Related]  

  • 11. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
    VON KNORRING
    Nord Med; 1964 Dec; 72():1443-6. PubMed ID: 14211013
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytogenetic studies in chronic myeloproliferative disorders.
    Carbonell F; Ganser A; Heimpel H
    Acta Haematol; 1983; 69(3):145-51. PubMed ID: 6404096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [THE PLACE OF OSTEOMYELOSCLEROSIS AMONG THE MYELOPROLIFERATIVE DISEASES].
    STOBBE H
    Dtsch Gesundheitsw; 1965 Jan; 20():13-20. PubMed ID: 14265017
    [No Abstract]   [Full Text] [Related]  

  • 18. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD
    Clin Haematol; 1980 Feb; 9(1):159-74. PubMed ID: 6768481
    [No Abstract]   [Full Text] [Related]  

  • 20. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
    Tefferi A
    Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.